BeStock  
Stocks › Biotechnology › MNPR

Monopar Therapeutics MNPR

US equityMarket cap rank #3666Biotechnology
$83.78 +$4.21 (+5.29%)
Pre-market · Oct 8, 8:20 am ET · After hours $83.80 +0.02%
Open$78.28
Prev close$79.57
Day range$77.98 – $85.03
Volume107.1K
Market cap$562.35M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$6.64M-105.4% YoY
Net profit-$5.31M-116.6% YoY
Diluted EPS-$0.62-77.1% YoY
Free cash flow-$3.25M-201.4% YoY
Operating cash flow-$3.25M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-1.3MSep '24$-10.9MDec '24$-2.6MMar '25$-2.5MJun '25$-3.4MSep '25$-5.2MDec '25$-3.9MMar '26$-5.3MJun '26

Diluted EPS by quarter

-0.37Sep '24-2.75Dec '24-0.38Mar '25-0.35Jun '25-0.48Sep '25-0.64Dec '25-0.46Mar '26-0.62Jun '26

Free cash flow by quarter

$-1.1MSep '24$-2.0MDec '24$-5.7MMar '25$-1.1MJun '25$-2.1MSep '25$-3.4MDec '25$-3.5MMar '26$-3.2MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-19.5%
Return on assets-18.9%
Return on invested capital-24.1%
Current ratio33.56
Liabilities / assets3.1%
Cash & investments$134.30M
Total debt$107,829.00
Net cash (debt)$134.19M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $6.64M $5.23M $16.70M $6.16M $4.09M
Selling and Admin Expenses $1.88M $1.74M $6.80M $2.21M $1.50M
-General & Admin Expense $1.88M $1.74M $6.80M $2.21M $1.50M
Research & Development $4.77M $3.49M $9.90M $3.94M $2.59M
Operating Profit -$6.64M -$5.23M -$16.70M -$6.16M -$4.09M
Net Non-Operating Interest Income (Expense) $1.30M $1.33M $2.99M $954,434.00 $655,473.00
Non-Operating Interest Income $1.30M $1.33M $2.99M $954,434.00 $655,473.00
Other Income (Expense) $32,158.00 – – – –
Other Non-Operating Income (Expenses) $32,158.00 – – – –
Pretax Profit -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Net Profit -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Profit from Continuing Operations -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Net Income to Parent Company -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Net Income to Common Stockholders -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Basic EPS -$0.62 -$0.46 -$1.85 -$0.64 -$0.48
Diluted EPS -$0.62 -$0.46 -$1.85 -$0.64 -$0.48

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $134.98M $137.98M $140.72M $140.72M $144.20M
Total Current Assets $134.76M $137.74M $140.46M $140.46M $144.09M
Cash and Cash Equivalents & Short-Term Investments $134.30M $137.49M $140.40M $140.40M $143.68M
-Cash and Cash Equivalents $52.76M $52.54M $61.83M $61.83M $127.68M
-Short Term Investments $81.54M $84.95M $78.57M $78.57M $16.00M
Other Current Assets $464,727.00 $250,903.00 $63,745.00 $63,745.00 $414,825.00
Total Non-Current Assets $215,120.00 $239,882.00 $254,921.00 $254,921.00 $106,666.00
Net PPE $215,120.00 $239,882.00 $254,921.00 $254,921.00 $106,666.00
-Gross PPE $215,120.00 $239,882.00 $254,921.00 $254,921.00 $106,666.00
Total Liabilities $4.12M $2.59M $2.89M $2.89M $2.64M
Total Current Liabilities $4.02M $2.46M $2.74M $2.74M $2.57M
Payables $4.02M $2.46M $2.74M $2.74M $2.57M
-Accounts Payable $4.02M $2.46M $2.74M $2.74M $2.57M
Total Non-Current Liabilities $107,828.00 $131,565.00 $154,920.00 $154,920.00 $70,881.00
Long Term Debt and Capital Lease Obligation $107,829.00 $131,565.00 $154,920.00 $154,920.00 $70,881.00
-Long Term Capital Lease Obligation $107,829.00 $131,565.00 $154,920.00 $154,920.00 $70,881.00
Other Non-Current Liabilities -$1.00 – – – –
Total Equity $130.85M $135.39M $137.83M $137.83M $141.56M
Stockholders' Equity $130.85M $135.39M $137.83M $137.83M $141.56M
Capital Stock $6,712.00 $6,699.00 $6,692.00 $6,692.00 $6,663.00
-Common Stock $6,712.00 $6,699.00 $6,692.00 $6,692.00 $6,663.00
Additional Paid-In Capital $229.47M $228.69M $227.20M $227.20M $225.85M
Retained Earnings -$98.72M -$93.40M -$89.51M -$89.51M -$84.31M
Gains/Losses Not Affecting Retained Earnings $91,317.00 $98,521.00 $131,389.00 $131,389.00 $11,698.00
Current Accrued Expenses – – $0.00 $0.00 $0.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$3.25M -$3.47M -$12.20M -$3.37M -$2.09M
Net cash flow from continuing operations -$3.25M -$3.47M -$12.20M -$3.37M -$2.09M
Net Income from Continuing Operations -$5.31M -$3.89M -$13.72M -$5.20M -$3.44M
Change in Working Capital $1.35M -$474,202.00 -$2.61M $1.44M $33,833.00
-Change in Payables and Accrued Expense $1.56M -$287,138.00 -$2.61M $738,682.00 $355,101.00
-Change in Other Current Assets -$213,822.00 -$187,039.00 $15,404.00 $709,403.00 -$321,268.00
-Change In Other Working Capital $0.00 -$25.00 -$9,432.00 -$5,002.00 $0.00
Net cash flow from investing $4.12M -$5.58M -$63.45M -$62.19M -$2.13M
Net Cash Flow from Continuing Investing Activities $4.12M -$5.58M -$63.45M -$62.19M -$2.13M
Net Investment Purchase and Sale $4.12M -$5.58M -$63.45M -$62.19M -$2.13M
Financing Cash Flow -$647,389.00 -$200,203.00 $91.57M -$384,680.00 $92.39M
Net Cash Flow from Continuing Financing Activities -$647,389.00 -$200,203.00 $91.57M -$384,680.00 $92.39M
Proceeds from Stock Option Exercised $7,575.00 $0.00 $565,171.00 $544,800.00 $214.00
Net Other Financing Charges -$654,964.00 -$200,203.00 -$1.13M -$298,094.00 -$381,563.00
Ending Cash Balance $52.76M $52.54M $61.83M $61.83M $127.68M
Net Change in Cash $220,645.00 -$9.26M $15.92M -$65.94M $88.18M
Beginning Cash Balance $52.54M $61.83M $45.82M $127.68M $39.50M
Effect of Exchange Rate Changes -$7,142.00 -$31,628.00 $97,266.00 $99,495.00 $376.00
Free Cash Flow -$3.25M -$3.47M -$12.20M -$3.37M -$2.09M
Net Common Stock Issuance – – $92.14M -$631,386.00 –

Discussion

No comments yet — be the first to weigh in on MNPR.

Leave a comment

Scroll to Top